Breaking News, Collaborations & Alliances

VERAXA Biotech Enters Co-Discovery Alliance with OmniAb

The partnership develops a novel bispecific antibody drug conjugate program targeting solid tumors.

By: Rachel Klemovitch

Assistant Editor

VERAXA Biotech AG (VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.  The collaboration combines OmniAb’s suite of transgenic antibody discovery solutions with VERAXA’s proprietary antibody drug conjugate (ADC) linker technology and conjugation expertise to support next-generation therapeutic discovery. Under the terms of the agreement, VERAXA will initiate a novel bispecif...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters